Allarity Therapeutics (ALLR) Short term Debt (2020 - 2026)

Allarity Therapeutics' (ALLR) quarterly Short term Debt came in at $20.1 million in Q1 2026, up 7932.0% on a QoQ basis from $250000.0 in Q4 2023.

Allarity Therapeutics (ALLR) Short term Debt (2020 - 2026) Analysis & Trends

Allarity Therapeutics (ALLR) has 5 years of Short term Debt data on file, last reported at $20.1 million in Q1 2026.

Quarterly Short term Debt changed N/A year-over-year to $20.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.1 million (changed N/A YoY) and the FY2023 annual result came in at $250000.0, down 90.54% from the prior year.
Short term Debt improved to $20.1 million in Q1 2026, from $250000.0 in the prior quarter.
In the past five years, Short term Debt ranged from a high of $20.1 million in Q1 2026 to a low of $250000.0 in Q4 2023.
A 3-year average of $6.4 million and a median of $2.7 million in 2022 frame the typical range for Short term Debt.
Annual changes were most pronounced in 2022 — Short term Debt decreased 0.86% — and 2023, when it tumbled 90.54%.
Tracing ALLR's Short term Debt over 3 years: stood at $2.6 million in 2022, then plunged by 90.54% to $250000.0 in 2023, then surged by 7932.0% to $20.1 million in 2026.
The last three Short term Debt figures came in at $20.1 million (Q1 2026), $250000.0 (Q4 2023), and $2.7 million (Q1 2023), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.75 Bn	130.90 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.96 Bn	77.96 Bn	3.93 Bn
3	Argenx Se	64.98 Bn	59.80 Bn	1.37 Bn
4	Moderna	56.33 Bn	51.19 Bn	52.00 Mn
5	BeOne Medicines	42.03 Bn	36.93 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.56 Bn	28.25 Bn	992.69 Mn
7	BioNTech SE	27.74 Bn	9.35 Bn	668.28 Mn
8	Insmed	27.47 Bn	26.31 Bn	358.27 Mn
9	Royalty Pharma	27.32 Bn	26.49 Bn	-
10	Allarity Therapeutics	22.75 Mn	22.75 Mn	-

Download Data